Géraldine Gontier & Grace Kim will be presenting insights from the VGCS-50635-002 study EventsRob MaguireOctober 24, 2024
Verge CEO Alice Zhang to be keynote speaker at the Longevity Platinum Trip EventsRob MaguireOctober 10, 2024
Diego Cadavid to present at 149th Annual Meeting of the American Neurological Association EventsRob MaguireSeptember 13, 2024
Verge Genomics CEO: Why I urge my employees to share their fears and vulnerabilities—and do the same with them NewsRob MaguireJune 6, 2024
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635 Press ReleaseRob MaguireMarch 25, 2024
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference Press ReleaseRob MaguireFebruary 21, 2024
Getting the most out of digital endpoints: case studies from Verge’s CMO NewsRob MaguireFebruary 15, 2024
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635 Press ReleaseRob MaguireJanuary 9, 2024
Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 Press ReleaseRob MaguireJanuary 3, 2024
Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635 Press ReleaseRob MaguireNovember 29, 2023
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration Press ReleaseRob MaguireOctober 31, 2023
CMO Diego Cadavid to participate in panel discussion at Fierce Biotech Summit EventsRob MaguireOctober 13, 2023
Verge to share initial results from the Phase 1 trial of VRG50635 at the American Neurological Association Annual Meeting EventsRob MaguireSeptember 12, 2023
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases Press ReleaseRob MaguireSeptember 8, 2023
